4/7/2024

Gentamicin Injection

Products Affected - Description

- Gentamicin injection, Hikma, 40 mg/mL, 2 mL vial, 25 count, NDC 00143-9128-25
- Gentamicin injection, Pfizer, 40 mg/mL, 2 mL vial, 25 count, NDC 00409-1207-03

Reason for the Shortage

- Baxter has gentamicin premixes available.
- Fresenius Kabi has gentamicin injection available.
- Hikma has gentamicin injection on shortage due to increased demand.
- Pfizer has gentamicin injection on shortage due to manufacturing delays.

Available Products

- Gentamicin injection, Baxter, 100 mg/100 mL, premixed bag, 24 count, NDC 00338-0505-48
- Gentamicin injection, Baxter, 100 mg/50 mL, premixed bag, 24 count, NDC 00338-0511-41
- Gentamicin injection, Baxter, 120 mg/100 mL, premixed bag, 24 count, NDC 00338-0507-48
- Gentamicin injection, Baxter, 60 mg/50 mL, premixed bag, 24 count, NDC 00338-0507-41
- Gentamicin injection, Baxter, 80 mg/100 mL, premixed bag, 24 count, NDC 00338-0503-48
- Gentamicin injection, Baxter, 80 mg/50 mL, premixed bag, 24 count, NDC 00338-0509-41
- Gentamicin injection, Fresenius Kabi, 10 mg/mL, 2 mL vial, 25 count, NDC 63323-0173-02
- Gentamicin injection, Fresenius Kabi, 40 mg/mL, 2 mL vial, 25 count, NDC 63323-0010-02
- Gentamicin injection, Fresenius Kabi, 40 mg/mL, 20 mL vial, 25 count, NDC 63323-0010-20

Estimated Resupply Dates

- Hikma has gentamicin 40 mg/mL 2 mL vials on back order and the company cannot estimate a release date.
- Pfizer has gentamicin 40 mg/mL 2 mL vials on back order and the company estimates a release date of August 2024.

Updated

Updated April 7, 2024 by Michelle Wheeler, PharmD, Drug Information Specialist. Created February 22, 2021 by Megan Dryer, PharmD. © 2024, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.